NASA’s New VTE Risk Score Algorithm for Astronauts

Spaceflight presents a physiological paradox: while microgravity shields the human body from the crushing force of gravity, it introduces novel, life-threatening risks. Among the most concerning is Venous Thromboembolism (VTE)—the formation of blood clots that can migrate to the lungs or brain. Following a series of incidents on the International Space Station (ISS), NASA has shifted from reactive, case-by-case medical management to a rigorous, data-driven framework.

On July 17, 2026, the NASA Office of the Chief Health and Medical Officer (OCHMO) released a formal, standardized clinical algorithm designed to assess VTE risk in astronauts. This milestone represents a transition toward proactive, mission-critical healthcare essential for the success of long-duration missions, including the upcoming Artemis program.

Understanding the VTE Risk Score Algorithm

The new algorithm acts as a standardized clinical gatekeeper, determining exactly when a crewmember requires prophylactic anticoagulation medication. Before this development, clinical decisions were often hampered by the lack of a universal scoring system, forcing flight surgeons to rely on individual judgment rather than a unified set of weighted benchmarks.

The core input is the identification of stasis in the left internal jugular vein (IJV). The working group, which finalized its findings in April 2026, identified this as a dominant physiological marker of clotting risk in microgravity. By combining space-specific ultrasound data with traditional terrestrial thrombosis risk factors—such as personal medical history and genetic predispositions—the algorithm calculates a weighted score to justify medical intervention.

Diagnostic Approaches: A Comparison

Feature	Previous Approach (Pre-2026)	New Algorithm (2026+)
Decision Basis	Clinical judgment/Anecdotal	Quantitative, weighted scoring
Primary Indicator	Vague clinical symptoms	Left Internal Jugular Vein (IJV) stasis
Standardization	Individual-based assessment	Unified, protocol-driven decision

Why This Matters for Deep Space Exploration

The transition to this standardized risk score is a vital prerequisite for human expansion beyond low-Earth orbit. On the ISS, rapid medical evacuation or advanced diagnostic support is theoretically possible. As NASA pivots toward the Artemis missions and eventual exploration of Mars, the reliance on high-latency, autonomous medical decision-making becomes paramount.

By quantifying risk today, the OCHMO is establishing the baseline of health maintenance required to keep crews safe when they are months away from the nearest terrestrial hospital. Standardizing this data ensures that flight surgeons have a clear, evidence-based protocol to prevent VTE before it becomes a mission-ending catastrophe.

Troubleshooting and Limitations: Addressing Hardware Gaps

The clinical team has identified a critical bottleneck: the limitations of current in-flight hardware. Experts noted that the ultrasound equipment currently stationed on the ISS faces challenges in accurately quantifying "slow flow" and subtle stasis patterns.

Because the algorithm relies on these ultrasound inputs, the accuracy of the risk score is tied to the fidelity of the imaging hardware. NASA has recommended an urgent review of in-flight ultrasound assessment protocols. If an astronaut’s score appears borderline, flight surgeons are advised to exercise caution, factoring in the potential for measurement error rather than relying solely on the device readout.